Monoclonal Antibodies that Neutralize Norovirus

Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks.

This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections.

Potential Commercial Applications: Competitive Advantages:
  • Therapeutics
  • Diagnostics
  • There are currently no vaccines or therapeutics available against Norovirus infections

Development Stage:
  • Early-stage
  • In vivo data available (animal)


Zhaochun Chen (NIAID)  ➽ more inventions...

Robert Purcell (NIAID)  ➽ more inventions...

Lisbeth Kim Green (NIAID)  ➽ more inventions...

Stanislav Sosnovtsev (NIAID)  ➽ more inventions...

Karin Bok (NIAID)  ➽ more inventions...

Intellectual Property:
US Pat: 9,534,041 issued 2017-01-03
PCT Pat: 9,815,887 issued 2017-11-14
US Application No. 14/767,274 filed on 2015-08-11
US Application No. 15/359,438 filed on 2016-11-22
European patent application is also available.

Chen Z, et al. PMID 23785216

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a therapeutic or a diagnostic for Norovirus infections. For collaboration opportunities, please contact Dr. Jenish Patel at or 240-669-2894.

Licensing Contact:
Peter Soukas, J.D.
Phone: 301-496-2644

OTT Reference No: E-226-2011-0
Updated: Jul 6, 2020